A rare case of sorafenib-induced severe hyponatremia.

Autor:	Khaja M; Division of Pulmonary/Critical Care Medicine, Bronx Care Health System, Icahn School of Medicine at Mount Sinai, Bronx, NY, USA., Torchon F; Division of Critical Care Medicine, New York-Presbyterian Lawrence Hospital Center, Columbia University Vagelos College of Physicians and Surgeons, Bronxville, NY, USA., Millerman K; Division of Critical Care Medicine, New York-Presbyterian Lawrence Hospital Center, Columbia University Vagelos College of Physicians and Surgeons, Bronxville, NY, USA.
Jazyk:	angličtina
Zdroj:	SAGE open medical case reports [SAGE Open Med Case Rep] 2019 Apr 28; Vol. 7, pp. 2050313X19846048. Date of Electronic Publication: 2019 Apr 28 (Print Publication: 2019).
DOI:	10.1177/2050313X19846048
Abstrakt:	Background: Sorafenib is an anti-angiogenic tyrosine kinase inhibitor used to treat patients with renal cell cancer and advanced hepatocellular cancer. Common adverse effects of sorafenib are rash, diarrhea, nausea, and abnormal liver function test and hand-foot syndrome. Case Presentation: Here, we present a case of a 90-year-old male who was prescribed sorafenib after being diagnosed with hepatocellular cancer. At 1 week after sorafenib initiation, he was admitted to the emergency room for an evaluation of weakness. The patient had hyponatremia, a common electrolyte abnormality seen in cancer patients. His hyponatremia improved when the sorafenib was stopped, suggesting that this was a rare case of hyponatremia induced by sorafenib. Conclusion: Although sorafenib is used in the treatment of hepatocellular cancer, it can cause life-threatening complication such as hyponatremia. Early identification of the cause of hyponatremia can prevent serious adverse event. Competing Interests: Declaration of conflicting interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu